Seeking Alpha

Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M...

Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M in milestones) with Novartis (NVS) to license its experimental cancer drug candidates.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs